Search results
University College London School of Pharmacy - Cited by 2,440 - Pharmaceutics - Pulmonary Drug Delivery
Studies investigating RNA therapeutics in pulmonary diseases have rapidly expanded and drug administration by inhalation allows the direct delivery of RNA therapeutics to the target site of action while minimizing systemic exposure.
- Michael Y.T. Chow, Michael Y.T. Chow, Yingshan Qiu, Jenny K.W. Lam
- 2020
Oct 1, 2020 · The largest obstacle in its clinical translation remains identifying a safe and effective delivery system. Studies investigating RNA therapeutics in pulmonary diseases have rapidly expanded and drug administration by inhalation allows the direct delivery of RNA therapeutics to the target site of action while minimizing systemic exposure.
- Michael Y.T. Chow, Michael Y.T. Chow, Yingshan Qiu, Jenny K.W. Lam
- 2020
This chapter provides an overview of inhaled therapy for the management of asthma and COPD. The operation principles, merits and limitations of different delivery technologies are examined. Looking ahead, the challenges of delivering novel therapeutics such as biologics through the pulmonary route are also discussed.
Michael Y.T. Chow's 33 research works with 1,650 citations and 21,161 reads, including: Delivery technology of inhaled therapy for asthma and COPD
Sep 4, 2020 · The studies are classified by (A) type of delivery vector; (B) disease model used; (C) administration method used in animal studies; and (D) RNA type. The classification was done independently by Y.Q. and M.C. and was cross-validated by J.K.W.L. Abbreviation: LIRI, lung ischemia–reperfusion injury.
The clustered regulatory interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (CRISPR/Cas9) system has significant therapeutic potentials for lung congenital diseases such as cystic fibrosis, as well as other pulmonary disorders like lung cancer and obstructive diseases.
